Mirabella (Ethinylestradiol, Gestodene)

Ethinylestradiol is a synthetic estrogen that suppresses the release of follicle‑stimulating hormone (FSH) from the pituitary gland. This reduces ovarian follicle development and stabilises the endometrium, contributing to the overall contraceptive effect when combined with a progestin such as gestodene.

The dosing regimen for Mirabella is determined by the prescribing clinician. Typically, the product is taken as one tablet daily at the same time each day, but the exact schedule and any break periods are set by the healthcare professional based on individual needs.

Mirabella is not intended for use during pregnancy and should be discontinued if pregnancy occurs. While limited data exist for breastfeeding, combined oral contraceptives are generally considered compatible with lactation, but the prescriber should evaluate the risk‑benefit balance for each patient.

To place an order, submit an enquiry on the Mirabella product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirabella contains ethinyloestradiol and gestodene, a low‑dose estrogen‑progestin combination that offers a favorable bleeding profile and a lower risk of certain side effects compared with higher‑dose formulations. Its efficacy in preventing pregnancy is comparable to other approved combined oral contraceptives, while tolerability may differ based on individual patient response.

Mirabella tablets should be stored at ambient temperature, preferably below 25 °C (77 °F). Keep the container tightly closed, protect it from moisture and direct sunlight, and store it in the original packaging until use.

Mirabella is administered orally as a tablet. The usual practice is to take one tablet each day, preferably at the same time, with or without food. Consistent daily intake helps maintain hormone levels and ensures optimal contraceptive effectiveness.

The most serious risks include venous thromboembolism such as deep‑vein thrombosis or pulmonary embolism, arterial events like stroke or myocardial infarction, and severe allergic reactions. Patients should seek immediate medical attention if they experience unexplained leg pain, shortness of breath, chest pain, severe headache, or signs of anaphylaxis.

Mirabella is contraindicated in women with a history of thromboembolic disorders, active or past breast cancer, uncontrolled hypertension, severe liver disease, known hypersensitivity to any component, and in smokers over 35 years of age. It should also be avoided during pregnancy.